SG11201407812SA - Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives - Google Patents

Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Info

Publication number
SG11201407812SA
SG11201407812SA SG11201407812SA SG11201407812SA SG11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA SG 11201407812S A SG11201407812S A SG 11201407812SA
Authority
SG
Singapore
Prior art keywords
international
methods
protein
aggregates
treatment
Prior art date
Application number
SG11201407812SA
Inventor
Peter Gagnon
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG11201407812SA publication Critical patent/SG11201407812SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/180650 A1 (51) International Patent Classification: C07K1/14( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/SG2013/000049 6 February 2013 (06.02.2013) English English (30) Priority Data: 61/653,752 31 May 2012 (31.05.2012) US (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). (72) Inventor: GAGNON, Peter; 20 Biopolis Way, #06-01 Centres, Singapore 138668 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road, Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) © o 00 i-H en i-H o CJ o & (54) Title: METHODS FOR REDUCING LEVELS OF PROTEIN-CONTAMINANT COMPLEXES AND AGGREGATES IN PROTEIN PREPARATIONS BY TREATMENT WITH ELECTROPOSITIVE ORGANIC ADDITIVES (57) Abstract: Methods for reduction of aggregate levels in antibody and other protein preparations through treatment with low con­ centrations of electropositive organic additives (e.g., ethacridine, chlorhexidine, or polyethylenimine) in combination with ureides (e.g., urea, uric acid, or allantoin) or organic modulators (e.g., nonionic organic polymers, surfactants, organic solvent or ureides). Some aspects of the invention relate to methods for reducing the level of aggregates in conjunction with clarification of cell culture harvest. It further relates to the integration of these capabilities with other purification methods to achieve the desired level of final purification.
SG11201407812SA 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives SG11201407812SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653752P 2012-05-31 2012-05-31
PCT/SG2013/000049 WO2013180650A1 (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Publications (1)

Publication Number Publication Date
SG11201407812SA true SG11201407812SA (en) 2014-12-30

Family

ID=49673721

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407812SA SG11201407812SA (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
SG10201606990TA SG10201606990TA (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201606990TA SG10201606990TA (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Country Status (8)

Country Link
US (1) US10246506B2 (en)
EP (1) EP2855502B1 (en)
JP (2) JP2015519361A (en)
KR (1) KR102067445B1 (en)
CN (1) CN104507953B (en)
IN (1) IN2014DN09948A (en)
SG (2) SG11201407812SA (en)
WO (1) WO2013180650A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505195TA (en) * 2013-02-06 2015-08-28 Agency Science Tech & Res Methods For Reducing Aggregate Content In Protein Preparations
US10112971B2 (en) * 2013-02-26 2018-10-30 Agency For Science, Technology And Research Protein purification in the presence of nonionic organic polymers and electropositive surfaces
KR20150122650A (en) * 2013-02-28 2015-11-02 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Protein purification in the presence of nonionic organic polymers at elevated conductivity
KR20160117628A (en) 2014-02-27 2016-10-10 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Methods for reducing aggregate content of protein preparations by treatment with aryl anions
EP3110829A4 (en) * 2014-02-27 2017-10-11 Agency for Science, Technology and Research Antibody purification process
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10927145B2 (en) 2016-06-15 2021-02-23 Agency For Science, Technology And Research Method of enhancing the performance of chromatography methods for purification of proteins
WO2018013673A1 (en) 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
DE102016010601B4 (en) 2016-09-01 2018-11-08 Sartorius Stedim Biotech Gmbh A process for the purification of viruses or virus-like particles using a crosslinked cellulose hydrate membrane
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
CN113493570B (en) * 2020-04-01 2022-11-01 中国科学院理化技术研究所 Method for reducing endotoxin in gelatin by adopting allantoin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
ATE222752T1 (en) * 1993-10-06 2002-09-15 Amgen Inc STABLE PROTEIN PHOSPHOLIPID COMPOSITIONS AND METHODS
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
SE9500778D0 (en) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE0201257D0 (en) * 2002-04-25 2002-04-25 Medical Invest In Sweden Ab Improved Separation
CN1286453C (en) * 2003-07-25 2006-11-29 复旦大学 Method for stablizing protein medicine and its application in microball preparation
CA2673851C (en) 2007-01-22 2016-05-03 Genentech, Inc. Polyelectrolyte precipitation and purification of proteins
EP2195330B1 (en) * 2007-10-12 2013-03-13 Merck Patent GmbH Method and agent for refolding proteins
EP2291388A4 (en) * 2008-06-03 2013-02-13 Patrys Ltd Process for purification of antibodies
EP2241886A1 (en) 2009-04-15 2010-10-20 Beckman Coulter Biomedical Limited Homogeneous agglutination immunoassay method and kit for such method
CA2812058C (en) * 2010-09-20 2019-04-16 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
WO2013180648A1 (en) * 2012-05-31 2013-12-05 Agency For Science, Technology And Research Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
EP2855504B1 (en) * 2012-05-31 2018-10-24 Agency For Science, Technology And Research Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities
EP2854980B1 (en) * 2012-05-31 2017-11-01 Agency For Science, Technology And Research Selective binding of biological targets to solid phase ureides

Also Published As

Publication number Publication date
CN104507953A (en) 2015-04-08
KR102067445B1 (en) 2020-01-17
CN104507953B (en) 2018-05-18
US20150148526A1 (en) 2015-05-28
IN2014DN09948A (en) 2015-08-14
EP2855502A1 (en) 2015-04-08
SG10201606990TA (en) 2016-10-28
EP2855502B1 (en) 2019-06-26
EP2855502A4 (en) 2016-02-17
JP2017222699A (en) 2017-12-21
JP2015519361A (en) 2015-07-09
KR20150028231A (en) 2015-03-13
US10246506B2 (en) 2019-04-02
WO2013180650A1 (en) 2013-12-05
JP6491277B2 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
SG11201407812SA (en) Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201407801VA (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
SG11201408261UA (en) Syringe
SG11201407774XA (en) Conversion of biomass
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201407200TA (en) Liquid formulation
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407424TA (en) Methods for determining information about a communication parameter and communication devices
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201406625XA (en) Anti-fcrn antibodies
SG11201408375RA (en) Transfers in multiple-deck elevator systems
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201407800SA (en) Selective binding of biological targets to solid phase ureides
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201805001UA (en) Method of treating influenza a
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch